PARKINSON’S DISEASE By Rachel Cheong. WHAT IS PARKINSON’S DISEASE?  Refers to Idiopathic/ Primary Parkinson’s Disease  Parkinsonism of unknown aetiology.

Slides:



Advertisements
Similar presentations
Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
An Overview of Conventional and Experimental Treatments
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Idiopathic parkinson’s disease (IPD)
Diagnosis and Treatment of Parkinson’s Disease Jeff Bronstein, MD, PhD Professor of Neurology at UCLA Director of the SW PADRECC Director of UCLA Movement.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Initial Diagnosis and Management of Parkinson’s Disease
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Parkinson’s Disease By Nik Sanyal.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Basal ganglia & cerebellar pathology
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
931-4 Convergence Insufficiency. History A 73-year old man with known PD for 10 years, complained of horizontal double vision for 18 months. He could.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Parkinson’s Disease. Definition Parkinson's disease (PD) is an idiopathic, slowly progressive, neurodegenerative disorder whereby two or more of the following.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Parkinson’s Disease superKAT :).
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
A neurology primer. Idiopathic Parkinson Disease (also referred to as primary or classical Parkinson disease)  is a progressive neurodegenerative disorder.
Neurological Disorders
second most common neurodegenerative disorder progressive loss of muscle control trembling of the limbs and head while at rest stiffness, slowness, and.
By Katelyn Chaimson and Sean Guyot
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Parkinson’s Disease Sheila Mulhern. Parkinson’s Disease Stats (PDF)  One million Americans live with Parkinson's disease, - more than the combined number.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Module 7.3 Movement Disorders
MOVEMENT DISORDERS.
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Atypical Parkinsonian Syndromes
Neurodegenerative diseases
Parkinson’s Disease Definitions Disease features Pathology
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

PARKINSON’S DISEASE By Rachel Cheong

WHAT IS PARKINSON’S DISEASE?  Refers to Idiopathic/ Primary Parkinson’s Disease  Parkinsonism of unknown aetiology  Parkinsinonism= tremor at rest, stiffness, slowing of movement and postural instability.  Part of the Movement Disorders known as Akinetic-Rigid syndromes  Akinetic-Rigid Syndromes= slowed movement, increased tone  Dyskinesias= added, uncontrollable movements  Definition: Degenerative, progressive disease affecting the zona compacta of the substantia nigra in the basal ganglia associated with decreased levels of dopamine

Akinetic-Rigid Syndromes Dyskinesias Idiopathic Parkinson’s DiseaseEssential tremor Drug-induced ParkinsonismChorea MPTP-induced ParkinsonismHemiballismus Postencephalitic ParkinsonismMyoclonus Parkinsonism-plusTics Wilson’s DiseaseDystonias Childhood akinetic-rigid syndromes Paroxysmal dyskinesias

IDIOPATHIC PARKINSON’S DISEASE  Described in 1817 by James Parkinson- “The Shaking Palsy”  Prevalence: 65.6 per 100,000 to 125 per 100,000.  UK Incidence= approx. 128,000 cases  Incidence increases severely with age:  from 17.4 in 100,000 person years between 50 and 59 years of age to 93.1 in 100,000 person years between 70 and 79 years  Slightly more common in men  Insidious onset and progression  Studies suggest patients born in the spring have a higher incidence of PD  Characterized by accumulation of alpha- synuclein into Lewy bodies in the neurons as a hallmark

 Related factors:  Nicotine: inverse relationship as acts like MAO- B inhibitors and stimulates dopamine  Caffeine may be protective  MPTP: methylphenyltetrahydropyridine (illicit stimulant/herbicides) causes severe parkinsonism  Encephalitis Lethargica: parkinsonism post- encephalitis  Genetics: (a) Familial clusters of early-onset PD (b) Mutations on Parkin gene on Chr 6 (under 40s; AR) (c) α -synuclein gene mutation on Chr 2p13 (d) Ubiquitin carboxyl terminal hydrolase L1 (UCHL1) gene on Chr 4p

Neuroanatomy Basal Ganglia =A large group of nuclei deep within the brain that affects movement. =Include the caudate nucleus & putamen (striatum), globus pallidus, subthalamic nucleus, and substantia nigra Substantia Nigra = Generates dopamine which regulates reward and movement.

PATHOPHYSIOLOGY The basal ganglia and the cerebellum transmit information via the thalamus to the cerebral cortex to regulate movement. In a healthy brain, the neurons in the substantia nigra release dopamine into the striatum  modulates neuronal activity  affects movements + behaviours. In Parkinson's disease, there is a breakdown in the connection between the striatum (neuron cells die/become impaired)  decreased dopamine levels Symptoms of Parkinson's disease appear after: 60% - 80% of the neuronal cells become impaired or die. Striatal dopamine levels have decreased by 20% - 50% of normal levels Subsequently, globus pallidus interna and subthalamic nucleus begin to function abnormally  Loss of control of motor function.

SIGNS & SYMPTOMS 1.Tremor- 4-7Hz pill-rolling tremor at rest (decreases with action) 2.Rigidity- lead-pipe/plastic rigidity, more marked on one side; Cogwheeling when occurs with tremor. 3.Akinesia/ Bradykinesia- poverty/slowing of movement; difficulty initiating movement; loss of fine-finger movements; micrographia; mask-like facial expression; serpentine stare (decreased blinking) 4.Postural/Gait Change- Stooping (Simian); festinant/shuffling gait with poor arm swing; balance deteriorates  falls 5.Monotonous, tremulous speech  slurring dysarthria  anarthria 6.Cognitive decline 7.Depression, Apathy, Anxiety 8.GI Sx- constipation, heartburn, dribbling, dysphagia, weight loss, urinary difficulties 9.Others- greasy skins, excessive sweating 10. Insomnia

DIAGNOSIS o Clinical diagnosis o NICE recommends using the UK Parkinson's Disease Society (PDS) Brain Bank Criteria for diagnosis: Step 1: diagnosis of Parkinsonian syndrome Bradykinesia + ≥ 1 of : Muscular rigidity. 4- to 6-Hz resting tremor. Postural instability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction. Step 2: exclusion criteria for Parkinson's disease: History of CVA/ step-wise progression/ head trauma/ / autonomic+cerebellar Sx/ Exposure to known drugs/ Negative response to Dopa trial/ Early severe dementia

Step 3: supportive prospective positive criteria of Parkinson's disease Three or more are required for the diagnosis of definite PD:  Unilateral onset.  Rest tremor present.  Progressive disorder.  Persistent asymmetry affecting the side of onset most.  Excellent response (70-100%) to L-dopa.  Severe L-dopa-induced chorea.  L-dopa response for five years or more.  Clinical course of ten years or more.  Hyposmia.  Visual hallucinations.

Investigations  To exclude other causes  CT/MRI: Exclude supratentorial tumours, normal pressure hydrocephalus and extensive subcortical vascular pathology.  Positron emission tomography (PET) scanning: with fluorodopa to localise dopamine deficiency in the basal ganglia  Transcranial sonography: differentiate PD from atypical or secondary Parkinsonian disorders, for early diagnosis of PD and for detection of subjects at risk for PD.  Genetic testing- eg, Huntington's gene, single- gene mutations in familial PD  Olfactory testing: differentiate PD from other Parkinsonian disorders  For young-onset or atypical disease: measurement of ceruloplasmin levels (Wilson's disease) and syphilis serology.

Management  NICE suggests specialist review every 6-12 months for clinical monitoring and medication adjustment  Multidisciplinary management including specialist nurses, OT, physiotherapy, SALT, psychologists, social services  Pharmacological Treatment:  Levodopa  Dopamine agonists  MAO-BIs  COMT inhibitors  Amantadine  Apomorphine  Antimuscarinic drugs  Surgical Treatment  Palliative Care

Levodopa  Most effective/ most responsive  Given with a peripheral dopa-decarboxylase inhibitor, which prevents peripheral conversion to dopamine  Eg: Sinemet, Madopar  Use lowest effective dose, eg: Sinemet 62.5 mg TDS increased to 125 mg after two weeks  Adverse effects rare/mild: nausea, dizziness, weight loss Dopamine agonists  Treats motor features  Used in early disease, younger patients  Can be adjuvant to Levodopa  More severe/common adverse effects than Levodopa  Non-ergot derivatives preferred, eg: pramipexole and ropinirole  Ergot-derivatives, eg: bromocriptine, cabergoline, lisuride and pergolide (Monitor renal function)

MAO-B Inhibitors  Eg: Selegiline, Rasagiline  Early treatment with selegiline alone can delay the need for levodopa therapy  Addition of selegiline to a levodopa/decarboxylase inhibitor combination is more effective when introduced at 5 years from onset COMT Inhibitors  Eg: Entacapone, Tolcapone  Reversibly inhibit the peripheral breakdown of levodopa by the COMT enzyme  Increases the amount available for conversion to dopamine in the brain and reducing fluctuations in plasma levels.  Benefits patients with levodopa motor fluctuations

Antimuscarinic drugs  Eg: orphenadrine, procyclidine and trihexyphenidyl  Improves motor function but common neuropsychiatric and cognitive S/E  Reduces drug-induced Parkinsonism Amantadine  monotherapy in early PD (for tremor or bradykinesia)  weak and short-lived benefit; used as adjuvant later Apomorphine  Given subcutaneously  Used as a rescue agent in advanced disease to provide rapid but short-lived benefit for sudden, severe 'off' episodes  use intermittent injections to reduce 'off time' and continuous infusion to reduce 'off time' and dyskinesias

Surgical Treatment  Developed in the mid-twentieth century before the advent of effective medical therapy.  Recently enjoyed a resurgence  Pallidotomy  Subthalamic Surgery  Thalamic Surgery  Deep Brain Stimulation

Complications  “Wearing Off Phenomenon” or “On-Off Fluctuations”  Dyskinesias  Depression & Anxiety  Hallucinations & Psychosis  Dementia  Compulsive Behaviours  Parkinsonian Crisis -Acute akinesia -rare but life-threatening complication -sudden worsening of motor symptoms and severe akinesia. -Triggers include infections, surgery, gastrointestinal disease and changes in medication. -Acute akinesia is difficult to treat and often needs hospital admission

Parkinson’s Plus Syndrome  Multiple System Atrophy -Shy-Drager Syndrome -autonomic dysfunction, parkinsonism, ataxia  Progressive Supranuclear Palsy - Steele-Richardson-Olszewski syndrome -Supranuclear ophthalmoplegia, neck dystonia, Parkinsonism, Pseudobulbar palsy, behavioral and cognitive impairment, imbalance and difficulties walking, frequent falls  Corticobasal Degeneration - Parkinsonism, Alien Hand Syndrome, Apraxia, Aphasia  Pick’s Disease - frontotemporal dementia, progressive nonfluent aphasia, impaired social conduct, passivity/anxiety

Case Scenario  A 64 year old man attends his GP after his wife made him come. For the last 6 months he has noticed that he is slowing down. It takes him a long time to do simple tasks like getting dressed. His hands are shaking all the time, more so on the right. His wife has noticed a change in his gait saying he shuffles when he walks. He has no past medical history of notes and is on no regular medication and has no known allergies. On examination he has a blank staring expression and marked rigidity of his limbs, more so on the right. He has resting pill rolling tremor. His gait is shuffling and festinant What is your differential diagnosis? What are the key Sx leading to your DDx?

References  NICE Guidelines pdf  University of Minnesota- Neurology Teaching Webpage  Kumar & Clark Pg  Oxford Handbook Pg , 534  Patient Plus Reference disease-management  International Parkinson’s and Movement Disorders Society kinson.php